Bioneer

064550 · KOSDAQ · Health Care · SMALL CAP

Net income turned to a loss.

Bioneer filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$55.5M (+10.75% year on year), an operating loss of US$516K (from a profit a year earlier) and a net loss of US$2.05M (from a profit a year earlier).

Earnings(Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-04-30· RCEPT 20260430901253

US$55.5MRevenue
+10.75%Revenue vs a year earlier
−US$516KOperating profit

Converted at 1 USD ≈ ₩1,474.01 (filing-date rate, 2026-04-30 close)

What happened

Bioneer filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$55.5M (+10.75% year on year), an operating loss of US$516K (from a profit a year earlier) and a net loss of US$2.05M (from a profit a year earlier).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$55.5M
Revenue vs a year earlier+10.75%
Operating profit−US$516K
Net income−US$2.05M
PeriodQ1 2026 (consolidated)
Filed2026-04-30, Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20260430901253 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-04-30 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.